지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.4
- 수록면
- 602 - 615 (14page)
- DOI
- 10.4143/crt.2023.726
이용수
초록· 키워드
오류제보하기
Purpose Patients with advanced biliary tract cancer (BTC) have a poor survival. We aim to evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine and cisplatin regimen in Chinese advanced BTC patients.Materials and Methods Eligible patients with locally advanced or metastatic BTC administrated intravenous 100 mg/m<sup>2</sup> nab-paclitaxel, 800 mg/m<sup>2</sup> gemcitabine, and 25 mg/m<sup>2</sup> cisplatin every 3 weeks. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and adverse events, while exploratory endpoint was the association of biomarkers with efficacy.Results After the median follow-up of 25.0 months, the median PFS and OS of 34 enrolled patients were 7.1 months (95% confidence interval [CI], 5.4 to 13.7) and 16.4 months (95% CI, 10.9 to 23.6), respectively. The most common treatment-related adverse events at ≥ 3 grade were neutropenia (26.5%) and leukopenia (26.5%). Survival analyses demonstrated that carcinoembryonic antigen (CEA) levels could monitor patients’ survival outcomes. A significant increase in the number of infiltrating CD4+ cells (p=0.008) and a decrease in programmed death-1–positive (PD-1+) cells (p=0.032) were observed in the response patients.Conclusion In advanced BTC patients, nab-paclitaxel plus gemcitabine and cisplatin regimen showed therapeutic potential. Potential prognostic factors of CEA levels, number of CD4+ cells and PD-1+ cells may help us maximize the efficacy benefit.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical Feasibility of Curative Surgery after nab-Paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Locally Advanced Cholangiocarcinoma
대한외과학회 학술대회 초록집
2022 .11
-
Surgical resection after gemcitabine, cisplatin, and nab-paclitaxel chemotherapy for locally advanced cholangiocarcinoma: A retrospective single-center study
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Surgical Resection after Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy for Locally Advanced Cholangiocarcinoma: A Retrospective Single-Center Study
대한외과학회 학술대회 초록집
2021 .05
-
[Surgical Oncology] Short-term Outcomes of Radical Surgery after nab-Paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Locally Advanced Perihilar Cholangiocarcinoma
대한외과학회 학술대회 초록집
2022 .11
-
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Cancer Research and Treatment
2015 .01
-
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
Gut and Liver
2022 .09
-
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Cancer Research and Treatment
2022 .04
-
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
Cancer Research and Treatment
2015 .01
-
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Cancer Research and Treatment
2021 .10
-
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
Cancer Research and Treatment
2017 .01
-
Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
Gut and Liver
2018 .01
-
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Journal of Gynecologic Oncology
2024 .07
-
Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
Yonsei Medical Journal
2021 .01
-
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Systemic Chemotherapy in Advanced Pancreatic Cancer
Gut and Liver
2016 .01
-
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3? CD4+ T Cells in Biliary Tract Cancer
Cancer Research and Treatment
2021 .01
최근 본 자료
댓글(0)
0